Last updated on November 2019

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole Based on Prior Endocrine Therapy in Patients With PIK3CA Mutation With Advanced Breast Cancer Who Have Progressed on or After Prior Treatments


Brief description of study

Study assessing the efficacy and safety of alpelisib plus fulvestrant or letrozole, based on prior endocrine therapy, in patients with PIK3CA mutation with advanced breast cancer who have progressed on or after prior treatments

Clinical Study Identifier: NCT03056755

Find a site near you

Start Over

Novartis Investigative Site

Heidelberg, Germany
9.15miles
  Connect »